# A Study of MT-4561 in Patients With Various Advanced Solid Tumors

> **NCT06943521** · PHASE1,PHASE2 · RECRUITING · sponsor: **Tanabe Pharma America, Inc.** · enrollment: 27 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Non-small Cell Lung Cancer (NSCLC)
- Esophageal Cancer
- Gastric Cancer
- Biliary Tract Cancer
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Breast Cancer
- Ovarian Cancer
- Cervical Cancer
- Endometrial Cancer
- Prostate Cancer
- Urothelial Carcinoma
- Neuroendocrine Tumor (NET)
- Neuroendocrine Carcinoma (NEC)
- Soft Tissue Sarcoma
- Nuclear Protein in Testis (NUT) Carcinoma

## Interventions

- **DRUG:** MT-4561

## Key facts

- **NCT ID:** NCT06943521
- **Lead sponsor:** Tanabe Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-18
- **Primary completion:** 2028-08
- **Final completion:** 2028-08
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2025-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06943521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06943521, "A Study of MT-4561 in Patients With Various Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06943521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*